The mechanism that reaches a founder's term sheet runs through the limited partner, not the partner in the meeting. When a fund's own investors are receiving about 6% of assets in distributions against a historical average near 14%, the recycling loop that funded the last decade of commitments is operating at well under half its normal pace: 6 divided by 14 is about 0.43 [3][2]. That is the arithmetic behind an extra three meetings.
The 2023 fundraising figure is the same story one step upstream. Just under $70bn, described as a 60% drop, implies a prior year near $175bn, since 70 divided by 0.4 is 175 [1][1]. Roughly $105bn of annual intake left the system in twelve months, and that supply was what made "raise the next round on schedule, at a higher price" a reasonable base case rather than a hope [1].
Run the distribution number forward and the pressure on general partners becomes legible. Four to five years into a 2021 vintage, 8 cents back per dollar committed is under two cents a year, taking 8 divided by 4.5 [2][3]. Distributions are back-weighted, so that is not a forecast of where those funds finish. It is a description of what a partner has to explain to their own backers before raising the next fund, which is the reason diligence has lengthened [2].
These figures come from a single contributor piece carrying Entrepreneur's standing note that contributor opinions are the author's own [14]. The direction is better supported than the decimals, and anyone sizing a financing plan should treat them accordingly.
The proposed stack does name a tradeoff that single-round plans tend to bury. Debt, venture debt, revenue-based financing and asset-backed lending are cheaper than equity and leave the cap table alone, and they must be repaid on a schedule regardless of how the market feels that quarter [9]. That discipline is an asset when revenue is predictable enough for a lender to underwrite and a liability when it is not, while equity, the most expensive capital in the stack, is the only source that will wait for an outcome [8]. A credible path to default-alive is what turns both into options instead of obligations, and its price is the growth you decline to buy [10].
A skeptic reading the same page would say the drought has already broken: IPO and secondary volume picked up in 2025, and dry powder raised in 2021 and 2022 is aging out into pressure to deploy in 2026 [4][6]. The contributor concedes both and qualifies both. The 2025 recovery sits in a small number of large, late-stage names, and the deployment pressure should loosen conditions without undoing scarcity for companies outside the hottest categories, which in any given quarter means outside the mostly-AI mega-rounds absorbing the large majority of dollars [4][5][6].
Which leaves sequencing as the live question rather than diagnosis. A company that wants a lender in the second half of 2026 needs underwritable revenue before it needs the lender, and that gets built in the quarter now underway [9]. The decision in front of most founders this quarter is one of eligibility: which of the three sources will still take their call a year from now, given what they put into the revenue line between now and then [7].
